A stepped-wedge randomized trial on the impact of early ART initiation on HIV patients' economic welfare in Eswatini

  1. Janina Isabel Steinert  Is a corresponding author
  2. Shaukat Khan
  3. Khudzie Mlambo
  4. Fiona J Walsh
  5. Emma Mafara
  6. Charlotte Lejeune
  7. Cebele Wong
  8. Anita Hettema
  9. Osondu Ogbouji
  10. Sebastian Vollmer
  11. Jan-Walter De Neve
  12. Sikhathele Mazibuko
  13. Velephi Okello
  14. Till Bärnighausen
  15. Pascal Geldsetzer
  1. Technical University of Munich, Germany
  2. Clinton Health Acccess Initiative, United States
  3. Duke University, United States
  4. University of Göttingen, Germany
  5. Heidelberg Institute of Global Health, Germany
  6. Ministry of Health of the Kingdom of Eswatini, Eswatini
  7. University of Heidelberg, Germany
  8. Stanford University, United States

Abstract

Background: Since 2015, the World Health Organisation (WHO) recommends immediate initiation of antiretroviral therapy (ART) for all HIV-positive patients. Epidemiological evidence points to important health benefits of immediate ART initiation; however, the policy's economic impact remains unknown. Methods: We conducted a stepped-wedge cluster-randomised controlled trial in Eswatini to determine the causal impact of immediate ART initiation on patients' economic welfare. Fourteen healthcare facilities were non-randomly matched in pairs and then randomly allocated to transition from the standard of care (ART eligibility at CD4 counts of < 350 cells/mm3 until September 2016 and <500 cells/mm3 thereafter) to the 'Early Initiation of ART for All' (EAAA) intervention at one of seven timepoints. Patients, healthcare personnel, and outcome assessors remained unblinded. Data was collected via standardised paper-based surveys with HIV-positive, ART-naïve adults who were neither pregnant nor breastfeeding. Outcomes were patients' time use, employment status, household expenditures and household wealth. Results: A total sample of 3,019 participants were interviewed over the duration of the study. The mean number of participants approached at each facility and time step varied from 4 to 112 participants. Using mixed-effects negative binomial regressions accounting for time trends and clustering, we found no significant difference between study arms for any economic outcome. Specifically, the EAAA intervention had no significant effect on non-resting time use (RR= 1.00, [CI: 0.96, 1.05, p=0.93]) or income-generating time use (RR= 0.94, [CI: 0.73,1.20, p=0.61]). Employment and household expenditures decreased slightly but not significantly in the EAAA group, with risk ratios of 0.93 [CI: 0.82, 1.04, p=0.21] and 0.92 [CI: 0.79, 1.06, p=0.26], respectively. We also found no significant treatment effect on households' asset ownership and living standards (RR=0.96, [CI 0.92, 1.00, p=0.253]). Lastly, there was no evidence of heterogeneity in effect estimates by patients' sex, age, education, timing of HIV diagnosis and ART initiation. Conclusions: Given the neutral effect on patients' economic welfare but positive effects on health, our findings support further investments into scaling-up immediate ART for all HIV patients. Trial Registration: ClinicalTrials.gov, NCT02909218 and NCT03789448; ethical approval: Eswatini National Health Service Review Board & Harvard T.H. Chan School of Public Health Review Board.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2-4 and all supplementary fogures (Figures S1-S9).

Article and author information

Author details

  1. Janina Isabel Steinert

    TUM School of Governance, Technical University of Munich, Munich, Germany
    For correspondence
    janina.steinert@tum.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7120-0075
  2. Shaukat Khan

    Clinton Health Acccess Initiative, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Khudzie Mlambo

    Clinton Health Acccess Initiative, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Fiona J Walsh

    Clinton Health Acccess Initiative, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Emma Mafara

    Clinton Health Acccess Initiative, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Charlotte Lejeune

    Clinton Health Acccess Initiative, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Cebele Wong

    Clinton Health Acccess Initiative, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Anita Hettema

    Clinton Health Acccess Initiative, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Osondu Ogbouji

    Duke Global Health Institute, Duke University, Durham, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Sebastian Vollmer

    Development Economics, University of Göttingen, Göttingen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  11. Jan-Walter De Neve

    Medical Faculty and University Hospital, Heidelberg University, Heidelberg Institute of Global Health, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0090-8249
  12. Sikhathele Mazibuko

    Ministry of Health of the Kingdom of Eswatini, Mbabane, Eswatini
    Competing interests
    The authors declare that no competing interests exist.
  13. Velephi Okello

    Ministry of Health of the Kingdom of Eswatini, Mbabane, Eswatini
    Competing interests
    The authors declare that no competing interests exist.
  14. Till Bärnighausen

    Institute of Public Health, University of Heidelberg, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  15. Pascal Geldsetzer

    Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.

Funding

Dutch Postcode Lottery in the Netherlands (NA)

  • Till Bärnighausen

Alexander von Humboldt-Stiftung

  • Till Bärnighausen

the Embassy of the Kingdom of the Netherlands in South Africa/Mozambique

  • Till Bärnighausen

British Columbia Centre of Excellence in Canada

  • Till Bärnighausen

Doctors Without Borders

  • Till Bärnighausen

National Center for Advancing Translational Sciences of the National Institutes of Health (Award Number KL2TR003143)

  • Pascal Geldsetzer

Joachim Herz Foundation

  • Janina Isabel Steinert

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Ethical approval for this study was obtained from the Eswatini National Health Service Review Board in July 2014 (Reference Number: MH/599C/FWA 000 15267). Respondents gave verbal and written consent before completing the interview and were informed about their right to decline or withdraw their participation at any point in time. The study was further granted an exemption for non-human subjects research from the ethics review board of the Harvard T.H. Chan School of Public Health.

Copyright

© 2020, Steinert et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 940
    views
  • 123
    downloads
  • 6
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Janina Isabel Steinert
  2. Shaukat Khan
  3. Khudzie Mlambo
  4. Fiona J Walsh
  5. Emma Mafara
  6. Charlotte Lejeune
  7. Cebele Wong
  8. Anita Hettema
  9. Osondu Ogbouji
  10. Sebastian Vollmer
  11. Jan-Walter De Neve
  12. Sikhathele Mazibuko
  13. Velephi Okello
  14. Till Bärnighausen
  15. Pascal Geldsetzer
(2020)
A stepped-wedge randomized trial on the impact of early ART initiation on HIV patients' economic welfare in Eswatini
eLife 9:e58487.
https://doi.org/10.7554/eLife.58487

Share this article

https://doi.org/10.7554/eLife.58487

Further reading

    1. Epidemiology and Global Health
    Riccardo Spott, Mathias W Pletz ... Christian Brandt
    Research Article

    Given the rapid cross-country spread of SARS-CoV-2 and the resulting difficulty in tracking lineage spread, we investigated the potential of combining mobile service data and fine-granular metadata (such as postal codes and genomic data) to advance integrated genomic surveillance of the pandemic in the federal state of Thuringia, Germany. We sequenced over 6500 SARS-CoV-2 Alpha genomes (B.1.1.7) across 7 months within Thuringia while collecting patients’ isolation dates and postal codes. Our dataset is complemented by over 66,000 publicly available German Alpha genomes and mobile service data for Thuringia. We identified the existence and spread of nine persistent mutation variants within the Alpha lineage, seven of which formed separate phylogenetic clusters with different spreading patterns in Thuringia. The remaining two are subclusters. Mobile service data can indicate these clusters’ spread and highlight a potential sampling bias, especially of low-prevalence variants. Thereby, mobile service data can be used either retrospectively to assess surveillance coverage and efficiency from already collected data or to actively guide part of a surveillance sampling process to districts where these variants are expected to emerge. The latter concept was successfully implemented as a proof-of-concept for a mobility-guided sampling strategy in response to the surveillance of Omicron sublineage BQ.1.1. The combination of mobile service data and SARS-CoV-2 surveillance by genome sequencing is a valuable tool for more targeted and responsive surveillance.

    1. Epidemiology and Global Health
    Marina Padilha, Victor Nahuel Keller ... Gilberto Kac
    Research Article

    Background: The role of circulating metabolites on child development is understudied. We investigated associations between children's serum metabolome and early childhood development (ECD).

    Methods: Untargeted metabolomics was performed on serum samples of 5,004 children aged 6-59 months, a subset of participants from the Brazilian National Survey on Child Nutrition (ENANI-2019). ECD was assessed using the Survey of Well-being of Young Children's milestones questionnaire. The graded response model was used to estimate developmental age. Developmental quotient (DQ) was calculated as the developmental age divided by chronological age. Partial least square regression selected metabolites with a variable importance projection ≥ 1. The interaction between significant metabolites and the child's age was tested.

    Results: Twenty-eight top-ranked metabolites were included in linear regression models adjusted for the child's nutritional status, diet quality, and infant age. Cresol sulfate (β = -0.07; adjusted-p < 0.001), hippuric acid (β = -0.06; adjusted-p < 0.001), phenylacetylglutamine (β = -0.06; adjusted-p < 0.001), and trimethylamine-N-oxide (β = -0.05; adjusted-p = 0.002) showed inverse associations with DQ. We observed opposite directions in the association of DQ for creatinine (for children aged -1 SD: β = -0.05; p =0.01; +1 SD: β = 0.05; p =0.02) and methylhistidine (-1 SD: β = - 0.04; p =0.04; +1 SD: β = 0.04; p =0.03).

    Conclusion: Serum biomarkers, including dietary and microbial-derived metabolites involved in the gut-brain axis, may potentially be used to track children at risk for developmental delays.

    Funding: Supported by the Brazilian Ministry of Health and the Brazilian National Research Council.